Additional Resources




  1. Abonia JP, Putnam PE. Mepolizumab in eosinophilic disorders. Expert Rev Clin Immunol. 2011:7(4):411-417.
  2. Accordini S, Cappa V, Braggion M, et al. The impact of diagnosed and undiagnosed current asthma in the general adult population. Int Arch Allergy Immunol. 2011;155(4):403-411.
  3. Apter AJ, Wan F, Reisine S, et al. The association of health literacy with adherence and outcomes in moderate-severe asthma. J Allergy Clin Immunol. 2013;132(2):321-327.
  4. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189-1197.
  5. Bjemer L, Lemiere C, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: A randomized phase 3 study. CHEST. 2016;150(4):789-798.
  6. Bleecker ER, FitzGerald M, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high dosage inhaled corticosteroids and long acting β2 agonists (SIROCCO): a randomised, multicenter, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115-2127.
  7. Boonpiyathat T, Sozener Z, Satitsuksanoa P, et al. Immunologic mechanisms in asthma. Semin Immunol. 2019;46:101333.
  8. Cote A, Godbout K, Boulet L. The management of severe asthma in 2020. Biochem Pharmacol. 2020;179:114112.
  9. Fox Huffaker M et al. Pediatric asthma: Guidelines-based care. omalizumab and other potential biologic agents. Immunol Allergy Clin North Am. 2015;35(1):129-144.
  10. Hanania NA, et al. Lebrikizumab in moderate-to-severe asthma: Pooled data from two randomised placebo-controlled studies. Thorax. 2015:70(8):748-756.
  11. Jarjour NN, Erzurum SC, Bleecker E, et al. Severe asthma. Lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med. 2012;185:356-362.
  12. Lambrecht B, Hammad H, Fahy J. The cytokines of asthma. Immunity. 2019;50(4):975-991.
  13. Laster N, Holsey CN, Shendell DG, et al. Barriers to asthma management among urban families: Caregiver and child perspectives. J Asthma. 2009;46(7):731-739.
  14. Moore WC, Bleeker ER, Curran-Evereh D, et al. Characterization of severe asthma phenotypes by the National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119(2):405-413.
  15. Nowak RM, Parker JM, Silverman RA, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. Am J Emerg Med. 2015;33:14-20.
  16. O’Byrne PM, Pedersen S, Schatz M, et al. The poorly explored impact of uncontrolled asthma. Chest. 2013;143(2):511-523.
  17. Ortega HG, Liu MC, et al. Treatment in patients with severe eosinophilic asthma. N Eng J Med. 2014:371:1198-1207.
  18. Rathinam K, Abraham J, Vijayakumar T.  Dupilumab in the treatment of moderate to severe asthma: An evidence-based review. Curr Ther Res Clin Exp. 2019;91:45-51.
  19. Reihman A, Holguin F, Sharma S. Management of severe asthma beyond the guidelines. Curr Allergy Asthma Rep. 2020;20(9):47.
  20. Rogliani P, Calzetta L, Matera M, et al. Severe asthma and biological therapy: when, which, and for whom. Pulm Ther. 2020;6(1):47-66.
  21. Russell R, Brightling CE. Anti-IL-5 for severe asthma. Chest. 2016;150(4):766-768.
  22. Sokol KC, Sharma G, Lin YL, et al. Choosing wisely: Adherence by physicians to recommended use of spirometry in the diagnosis and management of adult asthma. Am J Med. 2015;128(5):502-508.
  23. Tan LD, Bratt JM, Godor D, Louie S, Kenyon NJ. Benralizumab: A unique IL-5 inhibitor for severe asthma. J Asthma Allergy. 2016;9:71-78.
  24. Tan R, Liew M, Lim H, et al. Promises and challenges of biologics for severe asthma. Biochem Pharmacol. 2020;179:114012.
  25. Vatrella A, Fabozzi I, Calabrese C, et al. Dupilumab: A novel treatment for asthma. J Asthma Allergy. 2014;7:123-130.
  26. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high dose inhaled corticosteroids plus a long acting β2 agonist: A randomised double-blind, placebo controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31-44.